CVTP联合化疗方案对初治和复治难治恶性淋巴瘤的临床疗效研究  

Clinical Study of Cyclophosphamidum-Vindesine-Tetrahydropyranyl-Prednisone Treatment for Patients with Initial and Recurrent and Refractory Malignant Lymphoma

作　　者：周仲昊[1] 赵晓红[1] 陆时运[1] 王晨[1] 王智[1] 

机构地区：[1]南京医科大学附属无锡市第二人民医院血液科,江苏无锡214000

出　　处：《现代生物医学进展》2016年第3期492-495,共4页Progress in Modern Biomedicine

摘　　要：目的:比较环磷酰胺-西艾克-吡柔比星-泼尼松(Cyclophosphamidum-Vindesine-Tetrahydropyranyl-Prednisone,CVTP)联合化疗方案对初治和复治、难治恶性淋巴瘤的临床疗效。方法:按照化疗史将102例恶性淋巴瘤患者分为初治组59例和复治难治组43例,两组患者均给予CVTP联合化疗方案治疗,比较两组化疗效果、外周血淋巴细胞亚群、毒副反应差别。结果:初治组患者部分缓解(partial remission,PR)率和总有效率(overall response rate,ORR)均显著高于对复治难治组,差异具有统计学意义(P<0.05);初治组患者治疗后CD3^+、CD4^+、CD4^+/CD8^++、NK细胞含量均显著高于复治难治组,CD8^+水平显著低于复治难治组,差异具有统计学意义(P<0.05);初治组患者化疗期间白细胞下降、血红蛋白下降、血小板减少、恶心呕吐发生率均显著低于复治难治组,差异具有统计学意义(P<0.05)。结论:CVTP联合化疗方案治疗初治恶性淋巴瘤近期疗效优于复治难治患者。Objective：To explore the clinical effects of Cyclophosphamidum-Vindesine-Tetrahydropyranyl-Prednisone（CVTP）on patients with initial and recurrent and refractory malignant lymphoma.Methods：102 cases of patients with malignant lymphoma were divided into initial treatment group（59 cases） and retreatment refractory group（43 cases）,they were treated by CVTP chemotherapy.The difference of the clinical effects,peripheral lymphocyte subsets and side effects between the two groups were compared.Results：The partial remission（PR） rate of initial treatment group and overall response rate（ORR） rate were higher than retreatment refractory group（P〈0.05）;the CD3-＋,CD4-＋,CD4-＋/CD8-＋,NK for the initial treatment group were higher than retreatment refractory group（P〈0.05）;the CD8-＋ for the initial treatment group were lower than retreatment refractory group（P〈0.05）.The rate of leukocyte decrease,hemoglobin decreased,thrombocytopenia,nausea and vomit for the initial treatment group were lower than retreatment refractory group（P〈0.05）.Conclusions：It has better clinical effects for the patients with initial malignant lymphoma than that for recurrent and refractory malignant lymphoma by using CVTP chemotherapy.

关 键 词：CVTP 恶性淋巴瘤 疗效 毒副反应 

分 类 号：R733.4[医药卫生—肿瘤]